Charles River Laboratories International, Inc.
CRL Real Time Price USD$CRL is featured in our Rob Bresnahan strategy.
All StrategiesRecent trades of CRL by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in CRL holdings by institutional investors
Quarterly net insider trading by CRL's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Former government officials who have lobbied for CRL
16 former government officials from 9 congressional offices at 5 lobbying firms have lobbied for CRL, most recently Jul 21, 2026.
-
Kimberlee Trzeciak Congress FDA. Dep. Commissioner; 8/23-1/25. Assoc. Commissioner Leg. Affairs; 2/2022-08/2023. House Com. Energy & Commerce: Chief Health Advisor, 2/22-4/19. Sen. Health Policy Advisor, 3/19-3/15. Rep. John D. Dingell - LD, 05/13-07/11. Sen. LA, 7/11-08/09, LA
-
Emily Wilkinson-Holland Congress Staff -Rep. Price (2010-11), LA: Rep. Grimm (2011-12), Rep. Black (2012-13), Sen.Vitter (2013-2015), Sen. Heller (2015-17), Policy Adv. to the Sec.- Dept of HHS (3/2017-8/2017), Sr Advisor to Administrator - Ctrs for Medicare & Medicaid (8/17- 5/19).
-
Christopher Davis House Staff Assistant, Legislative Assistant, Senior Legislative Assistant, and Legislative Director - Rep. Rick Boucher (2006-2011). -
Brian Sutter House Staff Dir. W&M Health subcommittee, Chairman Dave Camp April'13-Dec'14. Professional Staff, W&M Health subcommittee, Chairman Dave Camp, Jan'11-April'13. Leg Dir. Rep Dave Camp, May'08-Jan'11. Leg Asst Rep Dave Camp, Feb'03-May'08. Staff Ast July'02
-
Remy Mason Senate Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz -
Maya Seiden House Intern, WH Counsels Office; Intern, Rep. Sam Gejdenson; Sp. Asst to Cab Sec., WH; Advisor to CoS, Energy Dept.; Sp Asst to Sec of Energy; Sen Advisor, Off of Dep. Sec of State; CoS Office of the Dep Sec of State for Management and Res. -
John Stone House Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C
-
Brent Del Monte House Leg. Dir. Rep. Bliley; Sen. Counsel House Energy & Commerce Committee
CRL Estimated quarterly lobbying spending
CRL Revenue by Segment or Geography
New CRL patent grants
-
Patent Title: Detection of infectious agents from environmental air dust Jun. 23, 2026
-
Patent Title: Detection of infectious agents from environmental air dust Mar. 03, 2026
-
Patent Title: Detection of infectious agents from environmental air dust Feb. 10, 2026
-
Patent Title: Laboratory instrument Jan. 20, 2026
-
Patent Title: Container Jan. 06, 2026
-
Patent Title: Cartridge Nov. 11, 2025
-
Patent Title: Cho host cell protein assay Mar. 25, 2025
-
Patent Title: Detection of infectious agents from environmental air dust Mar. 04, 2025
-
Patent Title: Recombinant amebocyte lysate and uses thereof Dec. 03, 2024
-
Patent Title: Recombinantly-modified adeno-associated virus (raav) having improved packaging efficiency Dec. 03, 2024
-
Patent Title: Articles and methods involving detection of binding Nov. 05, 2024
-
Patent Title: Cho host cell protein assay Mar. 08, 2022
-
Patent Title: Heat-treated limulus amebocyte lysates Jan. 11, 2022
-
Patent Title: Method for mass humanization of non-human antibodies Sep. 21, 2021
-
Patent Title: Porous planar cell capture system and method of use Apr. 13, 2021
-
Patent Title: Detection of infectious agents from environmental air dust Mar. 23, 2021
-
Patent Title: Heat-treated Nov. 12, 2019
-
Patent Title: Heat-treated limulus amebocyte lysates Nov. 12, 2019
-
Patent Title: Ringed membrane Sep. 10, 2019
-
Patent Title: Filtration system Oct. 16, 2018
-
Patent Title: Depressor Sep. 25, 2018
-
Patent Title: Membrane holder Sep. 25, 2018
-
Patent Title: Scanning device adapter Jun. 26, 2018
-
Patent Title: Blister Jun. 26, 2018
-
Patent Title: Optical method for detecting viable microorganisms in a cell sample Jul. 18, 2017
-
Patent Title: Filtration system and use thereof Apr. 18, 2017
-
Patent Title: Filtration device Mar. 28, 2017
-
Patent Title: Adapter Jan. 10, 2017
-
Patent Title: Base Jan. 10, 2017
-
Patent Title: Cup Jun. 21, 2016
-
Patent Title: Cup Jun. 21, 2016
-
Patent Title: Cup May. 05, 2015
-
Patent Title: Cup assembly Apr. 14, 2015
-
Patent Title: Fluorescence-based viability staining method using a membrane permeable flourescent dye and membrane impermeable fluorescence quencher Mar. 31, 2015
-
Patent Title: Method of viability staining with membrane permeable fluorescent dye and membrane impermeable fluorescence quencher Mar. 31, 2015
-
Patent Title: Cup Mar. 17, 2015
-
Patent Title: Base assembly Nov. 11, 2014
-
Patent Title: Base Nov. 11, 2014
-
Patent Title: Cell capture system Nov. 11, 2014
-
Patent Title: Base with membrane and support May. 20, 2014
-
Patent Title: Base May. 20, 2014
-
Patent Title: Stage May. 13, 2014
-
Patent Title: Lid Feb. 04, 2014
-
Patent Title: Methods for the detection and/or quantification of gram positive bacterial contaminants May. 14, 2013
-
Patent Title: Computer display with a graphical user interface Sep. 18, 2012
-
Patent Title: Computer display with a graphical user interface Sep. 18, 2012
-
Patent Title: Computer display with a graphical user interface Sep. 11, 2012
-
Patent Title: Methods for the detection and/or quantification of gram positive bacterial contaminants Jun. 28, 2011
-
Patent Title: Methods for the detection of microbial contaminants May. 10, 2011
-
Patent Title: Method for classifying a microorganism in a biological sample Mar. 08, 2011
Federal grants, loans, and purchases
Estimated quarterly amount awarded to CRL from public contracts
Recent insights relating to CRL
Recent picks made for CRL stock on CNBC
ETFs with the largest estimated holdings in CRL
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $CRL stock a Buy, Sell, or Hold?
- What is the price target for $CRL stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $CRL stock?
- Who owns the most shares of $CRL stock?
- What funds own $CRL stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CRL Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
- Address Wilmington, MA
- Market Cap 14.4 billion
- Employees 19,700
- Industrial Classification Services-Commercial Physical & Biological Research
Charles River Laboratories International, Inc. (CRL) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Charles River Laboratories International, Inc. (CRL).
Quiver Premium charts CRL's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at CRL, per a recent SEC DEF 14A filing. We estimate that the median employee at CHARLES RIVER LABORATORIES INTERNATIONAL, INC. is paid $55,870.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|